Adam Buckholz, MD
Hepatology · New York, NYNPI 1588026876
Payments from drug & device makers
What this record shows
12 manufacturers reported payments, led by Nonin Medical, Inc. at 41.0% of the total. 2025 is the largest year on record at $1,311, more than ten times the $117 reported in 2021. That places this record below the midpoint for hepatology clinicians in NY, where the typical reported total is $12,587.
Across 31 payments — averaging $81.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nonin Medical, Inc.$1K
- AbbVie$459
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$261
- Madrigal Pharmaceuticals$177
- Mirum Pharmaceuticals, Inc.$150
- Boston Scientific$127
- plus $312 from 6 others
What the payments were for
- Food & beverage$1,48559%
- Other$1,03041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nonin Medical, Inc. | 1 | $1,030 |
| AbbVie | 14 | $459 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $261 |
| Madrigal Pharmaceuticals | 2 | $177 |
| Mirum Pharmaceuticals, Inc. | 1 | $150 |
| Boston Scientific | 1 | $127 |
| Novo Nordisk | 1 | $125 |
| QOL Medical, LLC | 2 | $62 |
| Gilead | 2 | $44 |
| Lilly USA, LLC | 2 | $41 |
| Ardelyx, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Model 3150$1,030
- Skyrizi$261
- XIFAXAN$242
- Livmarli$150
- RESMETIROM$136
- EXALT Model D$127
How this compares
$2,515 in reported general payments places this provider in the 30th percentile of 29 hepatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ursodiol | 12 | $3,393 |
| Carvedilol | 14 | $132 |
| Famotidine | 12 | $90 |
Paid to pharmacies, not to this prescriber.
Other hepatology in New York
- Robert BrownNew York$967K
- Douglas DieterichNew York$830K
- Arun JesudianNew York$828K
- Albert MinNew York$277K
- Meena BansalNew York$208K
- Tatyana KushnerNew York$181K
- Howard WormanNew York$119K
- Augusto Villanueva RodriguezNew York$33K
- Jawad AhmadNew York$30K
- Joseph OdinNew York$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.